NO20054892L - Anti-IL-22RA-antistoffer og bindingspartnere og fremgangsmater for anvendelse ved inflammasjon - Google Patents
Anti-IL-22RA-antistoffer og bindingspartnere og fremgangsmater for anvendelse ved inflammasjonInfo
- Publication number
- NO20054892L NO20054892L NO20054892A NO20054892A NO20054892L NO 20054892 L NO20054892 L NO 20054892L NO 20054892 A NO20054892 A NO 20054892A NO 20054892 A NO20054892 A NO 20054892A NO 20054892 L NO20054892 L NO 20054892L
- Authority
- NO
- Norway
- Prior art keywords
- antibodies
- binding partners
- methods
- inflammation
- antagonizing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45748103P | 2003-03-24 | 2003-03-24 | |
US52329503P | 2003-11-17 | 2003-11-17 | |
PCT/US2004/008956 WO2004085476A2 (en) | 2003-03-24 | 2004-03-24 | Anti-il-22ra antibodies and binding partners and methods of using in inflammation |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20054892D0 NO20054892D0 (no) | 2005-10-21 |
NO20054892L true NO20054892L (no) | 2005-12-23 |
Family
ID=33101289
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20054892A NO20054892L (no) | 2003-03-24 | 2005-10-21 | Anti-IL-22RA-antistoffer og bindingspartnere og fremgangsmater for anvendelse ved inflammasjon |
Country Status (16)
Country | Link |
---|---|
US (6) | US20040209330A1 (de) |
EP (2) | EP1606316A2 (de) |
JP (2) | JP2007525438A (de) |
KR (3) | KR20110091598A (de) |
CN (2) | CN103864934A (de) |
AT (1) | ATE475673T1 (de) |
AU (2) | AU2004223837C1 (de) |
BR (2) | BRPI0408705A (de) |
CA (2) | CA2519089C (de) |
DE (1) | DE602004028347D1 (de) |
DK (1) | DK1606317T3 (de) |
EA (2) | EA009026B1 (de) |
ES (1) | ES2347657T3 (de) |
MX (2) | MXPA05010134A (de) |
NO (1) | NO20054892L (de) |
WO (2) | WO2004085476A2 (de) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5965704A (en) * | 1997-08-05 | 1999-10-12 | Zymogenetics, Inc. | Class two cytokine receptor-11 |
US6610286B2 (en) | 1999-12-23 | 2003-08-26 | Zymogenetics, Inc. | Method for treating inflammation using soluble receptors to interleukin-20 |
ES2381650T3 (es) * | 2000-08-08 | 2012-05-30 | Zymogenetics, Inc. | Receptores de citoquinas Zcytor11 solubles |
EP1803733B1 (de) | 2000-09-15 | 2010-03-10 | ZymoGenetics, Inc. | Polypeptide enthaltend extrazellulären Domäne von IL-20RA und/oderr IL-20RB |
IL161978A0 (en) | 2001-12-17 | 2005-11-20 | Zymogenetics Inc | Method for treating cervical cancer |
KR20110091598A (ko) * | 2003-03-24 | 2011-08-11 | 지모제넥틱스, 인코포레이티드 | 항-il-22ra 항체 및 결합 파트너 및 염증에 있어서의 사용 방법 |
EP2143733A1 (de) * | 2003-11-21 | 2010-01-13 | ZymoGenetics, Inc. | Anti-il-20-Rezeptor-Antikörper und Bindungspartner und Verfahren zur Anwendung bei Entzündungen |
KR20070073863A (ko) * | 2004-10-04 | 2007-07-10 | 트리니티 바이오시스템스, 인크. | 거대분자의 무침 전달을 위한 방법 및 조성물 |
PT1812476E (pt) | 2004-10-22 | 2010-11-08 | Zymogenetics Inc | Anticorpos anti-il-22ra e parceiros de ligação e métodos de utilização no tratamento de inflamações |
CN100515491C (zh) * | 2005-01-04 | 2009-07-22 | 健能隆医药技术(上海)有限公司 | 白介素-22的医药用途 |
AU2006212807A1 (en) * | 2005-02-08 | 2006-08-17 | Zymogenetics, Inc. | Anti-IL-20, anti-IL-22 and anti-IL-22RA antibodies and binding partners and methods of using in inflammation |
AU2006342792A1 (en) * | 2005-12-02 | 2007-11-08 | Genentech, Inc. | Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to IL-22 and IL-22R |
US7666991B2 (en) * | 2005-12-05 | 2010-02-23 | Trinity Biosystems, Inc. | Compositions for needleless delivery of antibodies |
EP1971367A4 (de) * | 2005-12-05 | 2010-04-07 | Trinity Biosystems Inc | Verfahren und zusammensetzungen zur nadellosen abgabe von bindungspartnern |
WO2007076422A2 (en) * | 2005-12-22 | 2007-07-05 | Dhy & Co., Ltd | Antibodies against interleukin-22 binding protein and its uses |
EP2010205A2 (de) * | 2006-03-16 | 2009-01-07 | Trinity Biosystems, Inc. | Verfahren zur erhöhung der grösse von tieren mit nadellos abgegebenen konstrukten |
JP5624276B2 (ja) | 2006-03-31 | 2014-11-12 | 中外製薬株式会社 | 抗体の血中動態を制御する方法 |
KR101557603B1 (ko) | 2006-06-08 | 2015-10-06 | 추가이 세이야쿠 가부시키가이샤 | 염증성 질환의 예방 또는 치료제 |
US20090092660A1 (en) * | 2006-08-09 | 2009-04-09 | Trinity Biosystems, Inc. | Methods and compositions for needleless delivery of particles |
ES2566957T3 (es) | 2007-09-26 | 2016-04-18 | Chugai Seiyaku Kabushiki Kaisha | Región constante de anticuerpo modificado |
EP3689912A1 (de) | 2007-09-26 | 2020-08-05 | Chugai Seiyaku Kabushiki Kaisha | Verfahren zur modifizierung eines isoelektrischen punkts eines antikörpers über aminosäuresubstitution in cdr |
BRPI0821145B8 (pt) | 2007-12-05 | 2021-05-25 | Chugai Pharmaceutical Co Ltd | uso de um anticorpo anti-nr10 como agente preventivo ou terapêutico para prurido |
EP2236604B1 (de) | 2007-12-05 | 2016-07-06 | Chugai Seiyaku Kabushiki Kaisha | Anti-nr10-antikörper und verwendung davon |
TWI564021B (zh) | 2008-04-11 | 2017-01-01 | Chugai Pharmaceutical Co Ltd | Repeated binding of antigen to antigen binding molecules |
RU2011101969A (ru) * | 2008-06-30 | 2012-08-10 | Ново Нордиск А/С (DK) | Антитела к человеческому интерлейкину-20 |
JP2010210772A (ja) * | 2009-03-13 | 2010-09-24 | Dainippon Screen Mfg Co Ltd | 液晶表示装置の製造方法 |
JP5717624B2 (ja) | 2009-03-19 | 2015-05-13 | 中外製薬株式会社 | 抗体定常領域改変体 |
TWI682995B (zh) | 2009-03-19 | 2020-01-21 | 日商中外製藥股份有限公司 | 抗體恆定區域改變體 |
US8454956B2 (en) * | 2009-08-31 | 2013-06-04 | National Cheng Kung University | Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies |
MX365235B (es) | 2010-11-30 | 2019-05-28 | Chugai Pharmaceutical Co Ltd | Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno. |
PL2686347T3 (pl) | 2011-03-16 | 2018-10-31 | Argenx Bvba | Przeciwciała przeciwko CD70 |
JP6141275B2 (ja) | 2011-08-05 | 2017-06-07 | ユニヴェルシテ デクス−マルセイユUniversite D’Aix−Marseille | 線維症感受性il22ra2遺伝子およびその使用 |
US8597647B1 (en) | 2012-05-22 | 2013-12-03 | National Cheng Kung University | Humanized anti-IL-20 antibody and uses thereof |
WO2014006230A1 (en) * | 2012-07-06 | 2014-01-09 | Novo Nordisk A/S | Il-20 epitopes and il-20 ligands |
WO2014015133A1 (en) | 2012-07-19 | 2014-01-23 | National Cheng Kung University | Treatment of osteoarthritis using il-20 antagonists |
US8603470B1 (en) | 2012-08-07 | 2013-12-10 | National Cheng Kung University | Use of IL-20 antagonists for treating liver diseases |
US8852588B2 (en) | 2012-08-07 | 2014-10-07 | National Cheng Kung University | Treating allergic airway disorders using anti-IL-20 receptor antibodies |
WO2014033252A1 (en) * | 2012-08-31 | 2014-03-06 | arGEN-X BV | Method for producing antibody molecules having inter-species, intra-target cross-reactivity |
US10391168B1 (en) | 2014-08-22 | 2019-08-27 | University Of Bern | Anti-CD70 combination therapy |
RU2683020C2 (ru) * | 2014-11-11 | 2019-03-26 | Петр Иванович Никитин | Субстанция и способ для модуляции активности агента в организме |
EP3284480A4 (de) | 2015-04-14 | 2018-12-05 | Chugai Seiyaku Kabushiki Kaisha | Pharmazeutische zusammensetzung zur prävention und/oder behandlung von atopischer dermatitis mit il-31-antagonisten als wirkstoff |
CN105601739B (zh) * | 2016-02-22 | 2019-01-18 | 王晨辉 | 一种人源化抗白介素22基因工程抗体及其应用 |
EP3464357A1 (de) | 2016-05-24 | 2019-04-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Verfahren und pharmazeutische zusammensetzungen zur behandlung von bakteriellen lungeninfektionen |
GB201612337D0 (en) * | 2016-07-15 | 2016-08-31 | Argen-X N V | Ant-il-22r antibodies |
JOP20190155A1 (ar) | 2016-12-21 | 2019-06-23 | Novartis Ag | مترافقات عقار جسم مضاد لإزالة خلايا جذعية مكونة للدم |
WO2020210816A1 (en) * | 2019-04-12 | 2020-10-15 | Methodist Hospital Research Institute | Therapeutic particles that enable antigen presenting cells to attack cancer cells |
EP3984553A4 (de) * | 2019-06-12 | 2023-07-19 | Acurasysbio Co., Ltd. | Zusammensetzung zur prävention oder behandlung von krebs |
AU2020387034A1 (en) | 2019-11-20 | 2022-06-02 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing preparation |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3654090A (en) | 1968-09-24 | 1972-04-04 | Organon | Method for the determination of antigens and antibodies |
US4331647A (en) * | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
EP0154316B1 (de) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemisch modifizierte Lymphokine und Verfahren zu ihrer Herstellung |
NZ212437A (en) * | 1985-06-17 | 1992-06-25 | Mark Philip Best | Site-directed antibody conjugates, and their preparation |
WO1989004838A1 (en) * | 1987-11-25 | 1989-06-01 | Immunex Corporation | Interleukin-1 receptors |
US4847325A (en) | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
US5567584A (en) * | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5436155A (en) * | 1991-12-31 | 1995-07-25 | Arch Development Corporation | Isolated DNA encoding a somatostatin receptor |
US5789192A (en) * | 1992-12-10 | 1998-08-04 | Schering Corporation | Mammalian receptors for interleukin-10 (IL-10) |
ATE203274T1 (de) | 1994-02-01 | 2001-08-15 | Nasa | Fusionierte proteine die antikörper-teile und nicht-antikörper-teile enthalten |
JP3713074B2 (ja) * | 1995-08-30 | 2005-11-02 | 栄研化学株式会社 | 血清アミロイドaを認識するモノクローナル抗体 |
US5843697A (en) | 1996-07-17 | 1998-12-01 | University Of Medicine And Dentistry Of New Jersey | Cells expressing IL-10 receptor and the CRFB4 gene product, an IL-10 receptor accessory protein |
US5985614A (en) * | 1996-08-30 | 1999-11-16 | Human Genome Sciences, Inc. | Polynucleotides encoding interleukin-19 |
US5945511A (en) * | 1997-02-20 | 1999-08-31 | Zymogenetics, Inc. | Class II cytokine receptor |
US6133426A (en) * | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
WO2000012708A2 (en) | 1998-09-01 | 2000-03-09 | Genentech, Inc. | Further pro polypeptides and sequences thereof |
WO2000078961A1 (en) | 1999-06-23 | 2000-12-28 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US6486301B1 (en) * | 1997-07-16 | 2002-11-26 | Human Genome Sciences, Inc. | Interleukin-20 |
WO1999003982A1 (en) | 1997-07-16 | 1999-01-28 | Human Genome Sciences, Inc. | Interleukin-20 |
KR100236609B1 (ko) * | 1997-08-01 | 2000-02-01 | 박호군 | 클로로하이드로실란 유도체 및 이의 제조방법 |
US5965704A (en) * | 1997-08-05 | 1999-10-12 | Zymogenetics, Inc. | Class two cytokine receptor-11 |
JP2001512668A (ja) | 1997-08-06 | 2001-08-28 | ザイモジェネティクス,インコーポレイティド | リポカリン相同体 |
US6551799B2 (en) * | 1999-12-07 | 2003-04-22 | Genentech, Inc. | Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders |
US6576743B1 (en) * | 1997-11-26 | 2003-06-10 | Zymogenetics, Inc. | Mammalian cytokine-like polypeptide-10 |
JP5191619B2 (ja) * | 1997-11-26 | 2013-05-08 | ザイモジェネティクス, インコーポレイテッド | 哺乳類のサイトカイン様ポリペプチド−10 |
NZ505880A (en) | 1998-01-23 | 2003-06-30 | Immunex Corp | IL-18 receptor polypeptides |
EP1062332A2 (de) | 1998-03-09 | 2000-12-27 | Schering Corporation | Menschliche rezeptorproteine; und verwandte reagenzien und verfahren |
DK1490386T3 (da) | 1998-03-10 | 2008-12-15 | Genentech Inc | Nyt polypeptid og nukleinsyrer kodende for dette |
US6197582B1 (en) * | 1998-03-18 | 2001-03-06 | The Trustees Of Columbia University In The City Of New York | Development of human monoclonal antibodies and uses thereof |
US6982320B2 (en) | 1998-03-19 | 2006-01-03 | Human Genome Sciences, Inc. | Cytokine receptor common gamma chain like |
WO1999061630A2 (en) | 1998-05-26 | 1999-12-02 | Regeneron Pharmaceuticals, Inc. | Chimeric molecules comprising an extracellular ligand binding domain of a receptor and an ige fc or constant region, and their use in an assay system |
BR9914777A (pt) | 1998-10-26 | 2001-07-03 | Ludwig Inst Cancer Res | Moléculas isoladas de ácido nucléico que codificam os fatores induzìveis por células t (tifs), as proteìnas codificadas e os usos das mesmas |
US6274710B1 (en) * | 1998-10-26 | 2001-08-14 | Ludwig Institute For Cancer Research | Antibodies which specifically bind T Cell inducible factors (TIFs) |
AU2222700A (en) | 1998-12-31 | 2000-07-31 | Millennium Pharmaceuticals, Inc. | Class ii cytokine receptor-like proteins and nucleic acids encoding them |
EP2357193B1 (de) | 1999-04-28 | 2015-11-04 | Genetics Institute, LLC | Menschliche GIL-19/AE289-Proteine und Polynukleotide zu deren Kodierung |
AU5151100A (en) | 1999-05-19 | 2000-12-05 | Incyte Genomics, Inc. | Extracellular signaling molecules |
WO2000073457A1 (en) | 1999-05-27 | 2000-12-07 | Schering-Corporation | Mammalian interleukin-10 homologs: il-d110 and il-d210 |
CA2372511C (en) | 1999-06-15 | 2011-11-22 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
IL147336A0 (en) | 1999-07-07 | 2002-08-14 | Zymogenetics Inc | Human cytokine receptor |
CA2380355A1 (en) | 1999-09-01 | 2001-03-08 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
EP1230368A2 (de) | 1999-11-18 | 2002-08-14 | Schering Corporation | Rezeptorproteine aus säugetieren; verwandte reagenzien und verfahren |
JP2003534773A (ja) | 1999-12-03 | 2003-11-25 | ザイモジェネティクス,インコーポレイティド | ヒトサイトカイン受容体 |
US6610286B2 (en) * | 1999-12-23 | 2003-08-26 | Zymogenetics, Inc. | Method for treating inflammation using soluble receptors to interleukin-20 |
CA2395369C (en) | 1999-12-23 | 2014-07-08 | Zymogenetics, Inc. | Cytokine zcyto18 |
JP4741139B2 (ja) | 1999-12-23 | 2011-08-03 | ザイモジェネティクス, インコーポレイテッド | 可溶性インターロイキン−20レセプター |
EP1616575B1 (de) * | 1999-12-23 | 2012-06-06 | ZymoGenetics, Inc. | Verfahren zur Behandlung von Entzündungen |
NZ523122A (en) | 2000-06-22 | 2004-06-25 | Smithkline Beecham Corp | Polypeptides and polynucleotides and methods of identifying agonists and antagonists in relation to treatment of diseases |
JP2002015498A (ja) * | 2000-06-29 | 2002-01-18 | Fujitsu Ltd | センス電流の設定方法 |
ES2381650T3 (es) * | 2000-08-08 | 2012-05-30 | Zymogenetics, Inc. | Receptores de citoquinas Zcytor11 solubles |
CN1452633A (zh) | 2000-09-08 | 2003-10-29 | 先灵公司 | 哺乳动物基因、相关试剂及方法 |
EP1803733B1 (de) | 2000-09-15 | 2010-03-10 | ZymoGenetics, Inc. | Polypeptide enthaltend extrazellulären Domäne von IL-20RA und/oderr IL-20RB |
US7268223B2 (en) | 2000-09-22 | 2007-09-11 | Wyeth | Isolated nucleic acid molecules which encode a soluble IL-TIF receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof |
US20030022827A1 (en) | 2000-09-25 | 2003-01-30 | Bertram Weiss | Three new members of the cytokine receptor family class 2 |
US7176180B2 (en) | 2001-01-12 | 2007-02-13 | Wyeth | Type 2 cytokine receptor and nucleic acids encoding same |
EP1390060A2 (de) | 2001-01-26 | 2004-02-25 | Eli Lilly And Company | Verwendung von lp82 zur behandlung von störungen des körpergewichtes |
EP1373319A2 (de) | 2001-02-23 | 2004-01-02 | Genetics Institute, LLC | Zusammensetzung die il-22 inhibitoren enthalten und deren verwendung zur behandlung von entzündungskrankheiten |
MXPA03007653A (es) * | 2001-02-28 | 2003-12-04 | Lilly Co Eli | Uso de lp82 para tratar trastornos hematopoyeticos. |
WO2002070655A2 (en) | 2001-03-02 | 2002-09-12 | Zymogenetics, Inc. | Mouse cytokine receptor |
EP1399472B1 (de) * | 2001-03-09 | 2009-06-03 | ZymoGenetics, Inc. | Löslicher heterodimerer cytokinrezeptor |
CA2439961A1 (en) | 2001-03-27 | 2002-10-03 | Zymogenetics, Inc. | Human cytokine receptor |
US7589180B2 (en) * | 2001-05-11 | 2009-09-15 | Abbott Laboratories Inc. | Specific binding proteins and uses thereof |
US20040204351A1 (en) | 2001-10-22 | 2004-10-14 | Rowlinson Scott William | Soluble proteins that inhibit cytokine signal transduction pathways |
DE10154579A1 (de) | 2001-11-07 | 2003-05-28 | Medigene Ag | Topikale Verwendung von Cytokinen und Chemokinen zur Behandlung von viralen oder mykotischen Hauterkrankungen oder Tumorerkrankungen |
IL161978A0 (en) | 2001-12-17 | 2005-11-20 | Zymogenetics Inc | Method for treating cervical cancer |
US20040236075A1 (en) | 2002-07-24 | 2004-11-25 | Laure Dumoutier | Novel glass II cytokine receptors, and uses thereof |
UA93179C2 (ru) * | 2003-03-24 | 2011-01-25 | Займоджинетикс, Инк. | Антитело, kotopoe специфически связывается c il-22ra, и способы его применения |
KR20110091598A (ko) | 2003-03-24 | 2011-08-11 | 지모제넥틱스, 인코포레이티드 | 항-il-22ra 항체 및 결합 파트너 및 염증에 있어서의 사용 방법 |
EP2143733A1 (de) | 2003-11-21 | 2010-01-13 | ZymoGenetics, Inc. | Anti-il-20-Rezeptor-Antikörper und Bindungspartner und Verfahren zur Anwendung bei Entzündungen |
PT1812476E (pt) * | 2004-10-22 | 2010-11-08 | Zymogenetics Inc | Anticorpos anti-il-22ra e parceiros de ligação e métodos de utilização no tratamento de inflamações |
-
2004
- 2004-03-24 KR KR1020117017412A patent/KR20110091598A/ko not_active Application Discontinuation
- 2004-03-24 JP JP2006507520A patent/JP2007525438A/ja active Pending
- 2004-03-24 EP EP04758097A patent/EP1606316A2/de not_active Withdrawn
- 2004-03-24 US US10/807,837 patent/US20040209330A1/en not_active Abandoned
- 2004-03-24 ES ES04749427T patent/ES2347657T3/es not_active Expired - Lifetime
- 2004-03-24 EP EP04749427A patent/EP1606317B1/de not_active Revoked
- 2004-03-24 DE DE602004028347T patent/DE602004028347D1/de not_active Expired - Lifetime
- 2004-03-24 WO PCT/US2004/008956 patent/WO2004085476A2/en active Application Filing
- 2004-03-24 BR BRPI0408705-4A patent/BRPI0408705A/pt not_active Application Discontinuation
- 2004-03-24 MX MXPA05010134A patent/MXPA05010134A/es unknown
- 2004-03-24 DK DK04749427.3T patent/DK1606317T3/da active
- 2004-03-24 MX MXPA05010136A patent/MXPA05010136A/es active IP Right Grant
- 2004-03-24 KR KR1020057017908A patent/KR20050116390A/ko not_active Application Discontinuation
- 2004-03-24 JP JP2006507519A patent/JP2007525437A/ja active Pending
- 2004-03-24 AU AU2004223837A patent/AU2004223837C1/en not_active Ceased
- 2004-03-24 WO PCT/US2004/008955 patent/WO2004085475A2/en active Application Filing
- 2004-03-24 AT AT04749427T patent/ATE475673T1/de active
- 2004-03-24 EA EA200501505A patent/EA009026B1/ru not_active IP Right Cessation
- 2004-03-24 CA CA2519089A patent/CA2519089C/en not_active Expired - Fee Related
- 2004-03-24 EA EA200501506A patent/EA009124B1/ru not_active IP Right Cessation
- 2004-03-24 US US10/807,997 patent/US20060134756A1/en not_active Abandoned
- 2004-03-24 CN CN201310173876.1A patent/CN103864934A/zh active Pending
- 2004-03-24 BR BRPI0408683-0A patent/BRPI0408683A/pt not_active Application Discontinuation
- 2004-03-24 KR KR1020057017960A patent/KR20050116392A/ko not_active Application Discontinuation
- 2004-03-24 CN CN2011101100944A patent/CN102690350A/zh active Pending
- 2004-03-24 AU AU2004223836A patent/AU2004223836A1/en not_active Abandoned
- 2004-03-24 CA CA002519057A patent/CA2519057A1/en not_active Abandoned
-
2005
- 2005-10-21 NO NO20054892A patent/NO20054892L/no not_active Application Discontinuation
-
2007
- 2007-11-27 US US11/945,975 patent/US20080233115A1/en not_active Abandoned
-
2008
- 2008-07-21 US US12/177,029 patent/US20090074661A1/en not_active Abandoned
-
2009
- 2009-10-16 US US12/580,987 patent/US8163286B2/en not_active Expired - Fee Related
-
2012
- 2012-03-22 US US13/427,077 patent/US20120207761A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20054892D0 (no) | Anti-IL-22RA-antistoffer og bindingspartnere og fremgangsmater for anvendelse ved inflammasjon | |
NO20072602L (no) | Anti-IL-22RA-antistoffer og bindingspartnere og fremgangsmater for anvendelse ved inflammasjon | |
MXPA06014465A (es) | Zcytor14 soluble, anticuerpos anti-zcytor14 y moleculas de union y metodos de uso en inflamacion. | |
WO2006086396A3 (en) | Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation | |
WO2005052000A3 (en) | Anti-il-20 antibodies and binding partners and methods of using in inflammation | |
DK1931697T3 (da) | IL-17A og IL-17F-antagonister og fremgangsmåder til anvendelse af disse | |
BR0314814A (pt) | Variantes otimizadas de fc e métodos para sua geração | |
WO2008039553A8 (en) | Soluble il-17rcx4 and methods of using in inflammation | |
DK1368060T3 (da) | HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme | |
EA200700823A1 (ru) | Растворимый zcytor21, анти-zcytor21 антитела и связывающие партнёры и способы применения при воспалении | |
EA200600314A1 (ru) | Использование растворимого cd164 при воспалительных и/или аутоимунных нарушениях | |
WO2005046714A3 (en) | Cytokine antagonist molecules | |
EA200500624A1 (ru) | Промотор для il-18bp, его получение и применение |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |